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Abstract  Ultrasound-guided  ﬁne  needle  sampling  is  proving  very  useful  for  avoiding  surgical
biopsy of  the  sentinel  lymph  node  for  N+  breast  cancer.  Because  of  its  high  speciﬁcity,  cytology
is sufﬁcient  in  most  cases.  Focal  or  diffuse  cortical  thickening  or  the  absence  of  the  echogenic
hilum irrespective  of  the  size  and  shape  of  the  lymph  node  are  ultrasound  signs  which  should
be taken  into  account.  The  status  of  the  lymph  nodes  in  axillary  and  extra-axillary  sites  has
an impact  on  the  later  management  of  patients  and  reduces  the  length  of  time  for  secondary
lymph node  dissection  and  adjuvant  therapy,  as  one  third  of  sentinel  ganglion  procedures  can
be avoided.  It  should  be  possible  to  optimise  identiﬁcation  of  the  sentinel  lymph  node  by  the
intradermal  injection  of  ultrasound  contrast  agent.  The  cost/effectiveness  ratio  is  positive  but
unknown and  should  be  assessed  in  the  initial  management  of  breast  cancer.
© 2012  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
With,  as  its  objective,  more  accurate  preoperative  staging  of  breast  tumours,  ﬁne  needle
lymph  node  sampling  can  be  proposed  for  choosing  between  a  sentinel  lymph  node  pro-
cedure  and  wider  dissection  or  neoadjuvant  chemotherapy.  We  shall  consider  the  value
of  lymph  node  ultrasonography  and  of  guided  sampling  for  the  diagnosis  of  lymph  node
metastase  and  the  impact  of  these  techniques  on  therapeutic  management.
Which lymph nodes should be sampled?
Clinical  examination  and  mammography  are  insufﬁcient  for  the  diagnosis  of  lymph  node
metastase  since  their  sensitivity  is  approximately  30%  while  their  speciﬁcity  is  high  at
greater  than  80%.  As  regards  ultrasonography,  the  criteria  are  usually  modiﬁcation  of
the  shape  and  ultrasound  structure  in  B  mode  and  modiﬁcation  of  the  vascularisation
in  colour  Doppler  mode  [1].  The  meta-analysis  by  Alvarez  et  al.  [2],  produced  after
E-mail address: balu-maestro.catherine@nice.unicancer.fr (C. Balu-Maestro).
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Figure 1. Lymphadenopathy. Focally-thickened cortex and ampu-
tation of the hilum although the shape is oval.
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metastasis  (greater  than  3  N+  and  greater  than  5  mm)  [11].
Finally,  a  Taiwanese  team  have  reported  the  usefulness  of
intraoperative  ultrasonography  for  detecting  non-sentinel
metastatic  lymph  nodes  [12,13],  reducing  the  level  of  false90  
eviewing  16  series,  including  14  prospective  studies  pub-
ished  between  1986  and  2003,  for  which  the  gold  standard
as  axial  lymph  node  dissection  in  11  studies  and  the  sen-
inel  lymph  node  procedure  and/or  wider  dissection  in  the  5
thers,  found  very  variable  values.  The  overall  sensitivity  of
ltrasonography  for  palpable  and  non-palpable  lymph  nodes
as  between  66.1%  and  72.7%,  and  the  speciﬁcity  between
4.1%  and  97.9%  based  on  the  criteria  of  size  (size  greater
han  5  mm  or  visible  lymph  node);  based  on  morphological
riteria  (circular  shape,  cortical  thickening,  hypoechogenic-
ty,  lobulation,  hilar  ﬁlling),  the  sensitivity  was  54.7%  to
2.2%  and  the  speciﬁcity  between  80.4%  to  97.1%.
If  non-palpable  nodes  alone  are  considered,  the  greatest
ensitivity  was  obtained  based  on  size  (73%  in  the  lymph
ode  dissection  series  and  60.9%  in  the  series  including
oth  lymph  node  dissection  and  the  sentinel  lymph  node
rocedure),  while  speciﬁcity  was  better  when  based  on  mor-
hological  criteria  (from  92.4%  to  96.5%  respectively).  In  this
eta-analysis,  better  sensitivity  was  found  for  non-palpable
odes  with  the  size  criterion  (greater  than  5  mm  or  visible
ymph  node)  than  with  the  morphological  criteria,  whereas
hatever  the  clinical  context,  speciﬁcity  was  always  greater
hen  the  morphological  criteria  were  considered.
In  the  more  recent  series,  since  the  meta-analysis  by
lvarez  et  al.  [2],  totalling  more  than  600  patients  [3—6],
ize  is  no  longer  considered  to  be  a  discriminating  element
nd  the  threshold  has  been  discussed.  For  Britton  et  al.  [5],
f  the  transverse  axis  is  greater  than  10  mm  the  hazard  ratio
s  7.4,  whereas  between  5  and  10  mm,  it  is  only  2.7.  Simi-
arly,  the  shape  classically  deﬁned  by  Solbiati  et  al.’s  index
7]  (long  axis/transverse  axis  [L/T]  less  than  2  for  a  patho-
ogical  lymph  node)  is  not  sufﬁciently  discriminating.  This
eeds  to  be  lowered  to  1.5  to  obtain  a  useful  speciﬁcity
f  84.4%  (versus  59%  if  L/T  less  than  2)  to  the  detriment
f  sensitivity  (45.9%  versus  59%).  At  the  present  time,  mor-
hological  alterations  are  more  speciﬁc  and  occur  earlier.
or  Esen  et  al.  [3],  the  sensitivity  of  ultrasonography  is  80%
nd  speciﬁcity  94%  if  the  morphological  criteria  are  con-
idered  exclusively.  The  greatest  predictive  signs  are  the
isappearance  or  the  eccentric  character  of  the  hilum  and
he  hypoechoic  character  of  the  cortex.  Normally,  the  hilum
s  twice  as  thick  as  the  cortex,  the  thickness  of  which  is
onsidered  as  pathological  when  it  is  greater  than  3  mm
or  concentric  thickenings  and  greater  than  2  mm  for  focal
hickenings  [5—8], aspects  which  are  related  to  the  invasion
f  the  lymph  node  by  afferent  lymphatics  (Figs.  1  and  2).
In  order  to  increase  the  sensitivity  of  ultrasonography,
ertain  authors  puncture  a  normal  lymph  node  or  nodes,
electing  the  largest  when  the  breast  tumour  is  larger  than
 cm  [9,10]  or  those  closest  to  the  tumour.  In  Doppler  mode,
nly  the  existence  of  cortical  vascularisation  seems  to  have
o  be  taken  into  account,  and  in  combination  with  B  mode
he  sensitivity  is  increased  by  10%  while  the  speciﬁcity  is
nchanged;  quantitative  criteria  do  not  seem  to  have  to  be
aken  into  account  [3].  Colour  Doppler  is  above  all  useful  for
isualising  vascular  landmarks  during  sampling  procedures,
ut  elastography  is  not  reported  in  this  application.  Results
ave  been  published  concerning  the  cervical  nodes  in  ENT
ancers.
False  positives  are  seen  as  hypoechoic  hila  usually
esulting  from  fatty  involution  (or  more  rarely  by  sinus  his-
iocytosis)  or  cortical  follicular  hyperplasia,  and  as  small
F
Tigure 2. Focal thickening (0.37 mm).
ymph  nodes  which  are  frequently  round  and  hypoechoic
Fig.  3).  False  negatives  are  represented  by  micrometas-
ases.  The  value  of  ultrasonography  increases  with  the  risk,
he  number  of  lymph  nodes  invaded  and  the  size  of  theigure 3. The cortex is focally thickened and the hilum reduced.
he biopsy is negative: ultrasound false positive.
Ultrasound-guided  lymph  node  sampling  in  the  initial  manageme
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OFigure 4. Targeted sampling from the cortex (arrow).
negatives  of  the  sentinel  lymph  node  procedure  (including
after  neoadjuvant  chemotherapy)  to  less  than  1.5%  [12,13].
What type of ﬁne needle sampling?
Samples  were  of  two  types:  cytological  with  21,  22  or
23  gauge  needles  with  or  without  aspiration,  targeted  on
the  cortex  and  multidirectional  when  the  hilum  was  still
present  and,  more  rarely,  microbiopsies  (14,  16,  21  G  tro-
cars)  (Fig.  4).  The  number  of  cytology  samples  was  generally
less  or  equal  to  3,  the  products  smeared  on  slides  and  usually
centrifuged  after  being  taken  up  in  a  CytoLit  solution.  Cer-
tain  authors  used  immunohistochemistry  [14,15]  to  increase
the  sensitivity  of  the  cytology.  As  for  microbiopsies,  2  to
5  cores  were  obtained  with  14  to  21  G  trocars,  depend-
ing  on  the  lesion  size  and  vascular  relations,  often  using  a
semi-automatic  gun.
What were the results of the guided
samples?
The  results  of  Alvarez  et  al.’  meta-analysis  [2]  came  from
prospective  studies  using  ultrasound-guided  ﬁne  needle
cytology  (apart  from  one  study  concerning  the  results  of
microbiopsies  [16]  and  a  retrospective  study  [17]). If  only
the  contributing  cytological  results  are  considered,  the  sen-
sitivity  varied  between  43.5  and  94.9%  and  the  speciﬁcity
between  96.9  and  100%.  When  these  results  are  added  to
those  of  the  population  initially  selected,  by  considering
patients  for  whom  the  ultrasound  examination  was  negative
and  those  whose  samples  were  not  contributive  as  false  neg-
atives,  the  sensitivity  falls  and  varies  between  30.6  to  62.9%.
Heterogeneity  in  both  cases  disappears  if  the  sentinel  lymph
node  procedures  are  excluded  that  generate  false  negatives,
but  other  biases  are  also  involved  —– selection  of  differ-
ent  stages,  surgical  or  radiological  recruitment,  different
equipment  —– while  the  ultrasound  sign  criteria  vary  little.
In  ﬁve  studies  [14,16—19]  only  suspect  lymph  nodes  were
punctured  whereas  in  three  studies,  [20—22], all  the  lymph
nodes  were  sampled  regardless  of  their  ultrasound  appear-
ance  or  their  size.  The  sensitivity  of  ﬁne  needle  cytology  is
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owered  because  the  procedure  requires  ultrasound  visual-
sation  of  the  lymph  nodes  and  for  it  to  be  technically
ossible;  speciﬁcity  is  constantly  excellent  (approximately
00%),  better  than  ultrasonography  alone  (80  to  96.5%
epending  on  the  morphological  criteria  for  N0  patients).
ew  studies  indicated  the  micro-  or  macrometastatic  char-
cter  of  the  false  negatives.  There  were  10  studies  later
han  the  meta-analysis  by  Alvarez  et  al.  (ﬁve  retrospective
9,10,23—25]  and  ﬁve  prospective  [11,15,26—28]  studies)
ublished  between  2005  and  2010,  and  for  clinical  N0
umours  they  reported  sensitivity  of  ultrasound-guided  ﬁne
eedle  cytology  of  between  50  and  62%  [10,24,25],  apart
rom  Baruah  et  al.’s  series  [28]  in  which  the  sensitivity  was
ow  (28%)  but  concerned  two  thirds  of  T1  classiﬁed  lesions
mong  the  502  patients  in  the  series.  One  series  [9]  sepa-
ated  out  the  results  of  samples  from  normal  lymph  nodes
nd  found  sensitivity  of  54%  [10]  with  a  false  negative  rate
rom  the  ultrasound  examination  of  13%,  this  result  detected
y  ﬁne  needle  cytology  of  these  lymph  nodes  that  exhib-
ted  no  ultrasound  abnormality  and  were  not  palpable.  The
eterogeneity  of  the  results  was  seen  to  be  related  to  the
tandard  technique  and  the  fall  in  sensitivity  when  non-
ontributive  cytological  products  were  included  (1  to  15%)
9,24,25].  The  results  are  signiﬁcantly  correlated:
with  tumour  size  (greater  than  2  cm)  with  35%  sensitivity
in  T1  versus  67%  in  T2  in  Somasundar  et  al.’s  series  [23],
56%  in  T1,  64%  in  T2,  82%  in  T3  and  100%  in  T4  in  Koalliker’s
series  [9];
with  grades:  for  Baruah  et  al.  [28], sensitivity  was  tripled
for  grade  3  compared  with  grade  1;
with  the  number  of  N+:  in  Van  Rijk  et  al.’s  study  [26]
the  number  of  N+  in  the  positive  cytologies  was  4.3  versus
2.2  in  the  negative  cytologies  for  an  identical  number  of
lymph  nodes  excised  (15).  In  Hinson  et  al.’s  series  [11],
the  sensitivity  was  66%  when  there  was  one  N+  and  100%
when  there  were  3  N+;
with  the  size  of  the  metastasis:  the  false  negatives  were
linked  to  micrometastases.  In  the  Alkuwari  and  Auger
study  [25], sensitivity  was  16%  in  the  sentinel  lymph  node
group  where  the  mean  size  of  the  metastasis  was  0.25  mm,
whereas  it  was  88%  in  the  lymph  node  dissection  group
where  the  mean  size  was  15  mm.  Nevertheless,  in  most
studies  which  have  assessed  this  criterion,  sensitivity  was
close  to  100%  above  5  mm.  In  three  studies  [11,19,29]  in
high  risk  patients,  when  the  size  of  the  metastasis  was
less  than  5  mm  and  there  was  a  single  N+,  all  the  cytolo-
gies  were  negative  even  if  the  ultrasound  examination  was
abnormal;
with  the  analysis  technique:  the  best  results  (80%)  were
found  in  the  series  which  used  an  immunohistochemical
technique  [14,15].
As  regards  the  microbiopsies,  with  an  18  G  calibre  in  1  to  3
ores,  Duchesne  [4]  reported  sensitivity  of  94%,  while  Dam-
ra  et  al.  [16]  with  1  to  2  14  G  cores  only  obtained  77%.  These
ates  were  lower  in  2  recent  series  including  normal  lymph
odes,  53.4%  for  Britton  et  al.  [5]  and  69.1%  for  Garcia-
rtega  [6].  In  this  series  of  291  biopsies  in  662  patients,
.9%  of  N+  were  found  in  the  samples  of  lymph  nodes  which
ad  a  normal  ultrasound  appearance  (lymph  node  dominat-
ng  by  size  or  the  lowest  in  the  axillary  region).  The  false
egatives  were  mainly  found  in  normal  lymph  nodes  and
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ultrasound  criteria  described  should  be  performed  on  a  rou-92  
n  single  cortical  lesions  [5].  Sensitivity  increased  with  the
rade  and  size  of  the  tumour  and  the  number  and  size  of
etastases  but,  despite  the  sampling  technique  used,  there
ere  27.6%  of  false  negatives  when  the  size  of  the  metastasis
as  between  5  and  10  mm  [30]. Speciﬁcity  was  100%  for  most
f  the  studies.  These  results  do  not  seem  to  lend  support
or  the  microbiopsy  technique  for  lymph  node  samples,  but
t  is  easier  to  perform  immunohistochemical  techniques  on
uch  specimens.  A  small  study  has  nevertheless  compared  22
ytological  samples  with  27  microbiopsy  samples  of  suspect
ymph  nodes  and  found  a  non-signiﬁcant  gain  (of  7%)  in  sensi-
ivity  but  double  the  ﬁnancial  cost  [31]. All  these  data  mean
hat  this  technique  is  not  considered  to  be  advantageous,  at
east,  not  as  a  ﬁrst  course  of  action.  Sever  et  al.  [32,33]
ecently  reported  the  possibility  of  identifying  the  sentinel
ymph  node  by  periareolar  injection  of  an  echogenic  con-
rast  agent  (0.2  to  0.5  mL  × 3 of  Sonovue®)  compared  with
sotopic  and  colorimetric  detection.  By  this  method,  the  sen-
inel  lymph  node  is  correctly  identiﬁed  in  89%  of  cases  as  well
s  all  the  N+.  Lymph  node  sampling  could  thus  be  correctly
argeted  on  the  sentinel  lymph  node  by  ultrasonography  with
ntradermal  injection.
hat is the beneﬁt?
he  number  of  sentinel  lymph  node  procedures  avoided  by
ymph  node  sampling,  redirecting  patients  to  axial  lymph
ode  dissection  from  the  outset,  was  estimated  for  ﬁne  nee-
le  cytology  in  nine  studies  [6,10,15,23,24,26—29]  and  was
etween  8%  [6]  and  50%  [3].  The  rate  of  28%  in  Baruah’s
eries  seems  closer  to  what  could  be  hoped  for  by  perform-
ng  ﬁne  needle  cytology.  For  microbiopsies,  Garcia-Ortega
valuated  it  as  33%  [6].  Houssami  et  al.’s  meta-analysis  in
011  concerning  31  studies  estimated  reconversion  to  lymph
ode  dissection  at  17.7%  for  infraclinical  lymph  nodes  char-
cterised  by  ﬁne  needle  cytology  or  biopsy  [34]. Patients
ere  redirected  to  neoadjuvant  chemotherapy  in  46%  of  the
ytology  cases  [10], 23%  of  the  positive  biopsy  cases  [6]  and
4%  of  T1  stages  [23]. In  Caroll  et  al.’s  recent  series  [34], the
ensitivity  of  lymph  node  ultrasonography  associated  with
ytology  and  the  size  of  the  sentinel  lymph  node  was  91%.
he  time  before  subsequent  management  was  considerably
educed  and  before  adjuvant  treatment  was  reduced  from
9  days  to  23.3  days  [35].
There  is  no  direct  evaluation  of  costs;  the  studies
oncerning  management  are  partial  or  incomplete,  are
ometimes  in  the  public  and  sometimes  in  the  private  sector.
eduction  in  cost  was  estimated  in  one  study  [29]  as  20%  for
 reduction  of  40%  in  recourse  to  the  sentinel  lymph  node
rocedure.  It  is  all  the  greater  the  higher  the  prevalence
f  N+.
s there an indication for guided sampling
efore neoadjuvant treatment?
ew  studies  have  evaluated  this  [12,13,23,25,36].
ltrasound-guided  ﬁne  needle  cytology  could  replace
he  sentinel  lymph  node  procedure  before  chemotherapy
o  distinguish  truly  N  negative  patients  from  those  made
egative  by  the  chemotherapy,  with  the  aim  of  choosing
t
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etween  sentinel  lymph  node  and  wider  lymph  node  dissec-
ion  during  surgery.  In  Khan  et  al.’s  series,  20  of  38  patients
nderwent  ﬁne  needle  cytology  before  chemotherapy  [36].
fter  treatment,  there  was  one  false  negative  case/14
+  cases  in  this  group  as  against  no  false  negatives  for  the
ight  N+  patients  initially  evaluated  by  the  sentinel  lymph
ode  procedure.
Given  its  speciﬁcity,  ﬁne  needle  cytology,  when  posi-
ive,  can  also  avoid  the  sentinel  lymph  node  procedure  for
retherapeutic  staging.  The  results  of  the  ﬁne  needle  cytol-
gy  of  normal  lymph  nodes  have  not  been  made  clear.  A
ulticentre  clinical  trial  is  underway  (GANEA2)  in  which
ne  needle  lymph  node  cytology  is  being  performed  where
here  is  a suspect  lymph  node  on  the  day  of  consultation
or  inclusion  in  the  protocol.  Intraoperative  ultrasonography
as  also  been  studied  in  this  indication,  as  mentioned  earlier
12,13].
s there an indication for guided sampling
f  parasternal lymph nodes?
he  presence  of  parasternal  lymph  nodes  stages  the  tumour
s  N2b  or  N3.  All  imaging  techniques,  CT,  MRI,  PET-CT  and
ltrasonography  can  visualise  them.  The  factors  predicting
nvasion  of  the  parasternal  lymph  nodes  are  the  existence
f  axillary  lymphadenopathies,  a  locally  advanced  tumour
rate  of  invasion  of  the  parasternal  chain:  28  to  52%),  deep
ocations  and  central  tumours.  They  mainly  occur  in  the  1st
nd  2nd  intercostal  spaces.  Irradiation  of  the  parasternal
hain  is  debated  because  of  cardiac  toxicity  and  a  disputed
mpact  on  survival.
However,  two  large  studies  in  2008,  reported  by  Veronesi
t  al.  [37]  and  Zhang  et  al.  [38], showed  that  irradia-
ion  had  an  impact  on  overall  survival  and  local  control.
eronesi’s  study  concerned  663  patients  who  underwent
urgical  biopsy  of  the  parasternal  lymph  nodes  (detected
ith  a  probe  with  or  without  scintigraphy)  and,  in  the
0.3%  of  them  that  had  been  invaded  the  parasternal  chain
as  irradiated.  Five-year  survival  was  greater  than  95%
nd  survival  without  recurrence  was  78%.  Zhang’s  study
oncerned  809  clinical  N2-3  patients:  112  parasternal  lym-
hadenopathies  were  detected  by  imaging  (ultrasonography,
T,  PET-CT)  and  in  all  the  10  cases  of  isolated  parasternal
nvolvement  (average  size  =  13  mm)  the  ultrasound-guided
iopsy  was  positive  [38]. At  5  years,  parasternal  control
as  89%,  local  control  80%  and  overall  survival  and  sur-
ival  without  recurrence  were  76%  and  56%  respectively.
re  these  data  sufﬁcient  to  suggest  cytological  checks  on
arasternal  lymph  nodes  seen  in  imaging,  particularly  using
ltrasonography?
n practice
ine  needle  cytology  of  suspect  lymph  nodes  deﬁned  by  theine  basis  as  soon  as  the  sentinel  lymph  node  procedure  is
nvisaged.  If  a  number  of  lymph  nodes  are  suspect  several
ites  may  be  selected,  the  choice  depending  essentially  on
he  size  and  accessibility.
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[Ultrasound-guided  lymph  node  sampling  in  the  initial  manag
Conclusion
Ultrasound-guided  ﬁne  needle  cytology  is  a  sensitive  and,
above  all,  very  speciﬁc  method.  False  negative  are  linked  to
problems  of  sampling  often  related  to  micrometastases  or
focal  invasion  less  than  5  mm  in  size.  This  method  should  be
optimised  by  puncturing  the  sentinel  lymph  node  more  pre-
cisely  and  in  this  context  intradermal  injection  of  a  contrast
agent  or  elastography  should  be  evaluated.  With  identi-
ﬁcation  of  lymph  node  metastases  at  the  time  of  initial
management  of  breast  cancer  the  sentinel  lymph  node  pro-
cedure  can  be  avoided  given  the  high  predictive  value  of  ﬁne
needle  cytology.  This  is  best  performed  at  the  same  time  as
biopsy  of  the  breast  tumour  to  avoid  inducing  false  positives
(linked  to  an  inﬂammatory  reaction)  both  for  the  radiologist
and  pathologist.  Microbiopsies  do  not  seem  to  be  essential
as  a  ﬁrst  course  of  action.  The  beneﬁts  in  terms  of  cost  of
such  a  strategy  have  not  yet  been  analysed.
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